AIMS/HYPOTHESIS: High-energy breakfast and reduced-energy dinner (Bdiet) significantly reduces postprandial glycaemia in obese non-diabetic individuals. Our objective was to test whether this meal schedule reduces postprandial hyperglycaemia (PPHG) in patients with type 2 diabetes by enhancing incretin and insulin levels when compared with high-energy dinner and reduced-energy breakfast (Ddiet). METHODS: In a randomised, open label, crossover design performed in a clinic setting, 18 individuals (aged 30-70 years with BMI 22-35 kg/m(2)) with type 2 diabetes (<10 years duration) treated with metformin and/or diet were given either Bdiet or Ddiet for 7 days. Participants were randomised by a person not involved in the study using a coin flip. Postprandial levels of plasma glucose, insulin, C-peptide and intact and total glucagon-like peptide-1 (iGLP-1 and tGLP-1) were assessed. The Bdiet included 2,946 kJ breakfast, 2,523 kJ lunch and 858 kJ dinner. The Ddiet comprised 858 kJ breakfast, 2,523 kJ lunch and 2,946 kJ dinner. RESULTS:Twenty-two individuals were randomised and 18 analysed. The AUC for glucose (AUCglucose) throughout the day was 20% lower, whereas AUCinsulin, AUCC-peptide and AUCtGLP-1 were 20% higher for the Bdiet than the Ddiet. Glucose AUC0-180min and its peak were both lower by 24%, whereas insulin AUC0-180min was 11% higher after the Bdiet than the Ddiet. This was accompanied by 30% higher tGLP-1 and 16% higher iGLP-1 levels. Despite the diets being isoenergetic, lunch resulted in lower glucose (by 21-25%) and higher insulin (by 23%) with the Bdiet vs Ddiet. CONCLUSIONS/ INTERPRETATION: High energy intake at breakfast is associated with significant reduction in overall PPHG in diabetic patients over the entire day. This dietary adjustment may have a therapeutic advantage for the achievement of optimal metabolic control and may have the potential for being preventive for cardiovascular and other complications of type 2 diabetes. Trial registration ClinicalTrials.gov NCT01977833 Funding No specific funding was received for the study.
RCT Entities:
AIMS/HYPOTHESIS: High-energy breakfast and reduced-energy dinner (Bdiet) significantly reduces postprandial glycaemia in obese non-diabetic individuals. Our objective was to test whether this meal schedule reduces postprandial hyperglycaemia (PPHG) in patients with type 2 diabetes by enhancing incretin and insulin levels when compared with high-energy dinner and reduced-energy breakfast (Ddiet). METHODS: In a randomised, open label, crossover design performed in a clinic setting, 18 individuals (aged 30-70 years with BMI 22-35 kg/m(2)) with type 2 diabetes (<10 years duration) treated with metformin and/or diet were given either Bdiet or Ddiet for 7 days. Participants were randomised by a person not involved in the study using a coin flip. Postprandial levels of plasma glucose, insulin, C-peptide and intact and total glucagon-like peptide-1 (iGLP-1 and tGLP-1) were assessed. The Bdiet included 2,946 kJ breakfast, 2,523 kJ lunch and 858 kJ dinner. The Ddiet comprised 858 kJ breakfast, 2,523 kJ lunch and 2,946 kJ dinner. RESULTS: Twenty-two individuals were randomised and 18 analysed. The AUC for glucose (AUCglucose) throughout the day was 20% lower, whereas AUCinsulin, AUCC-peptide and AUCtGLP-1 were 20% higher for the Bdiet than the Ddiet. Glucose AUC0-180min and its peak were both lower by 24%, whereas insulin AUC0-180min was 11% higher after the Bdiet than the Ddiet. This was accompanied by 30% higher tGLP-1 and 16% higher iGLP-1 levels. Despite the diets being isoenergetic, lunch resulted in lower glucose (by 21-25%) and higher insulin (by 23%) with the Bdiet vs Ddiet. CONCLUSIONS/ INTERPRETATION: High energy intake at breakfast is associated with significant reduction in overall PPHG in diabeticpatients over the entire day. This dietary adjustment may have a therapeutic advantage for the achievement of optimal metabolic control and may have the potential for being preventive for cardiovascular and other complications of type 2 diabetes. Trial registration ClinicalTrials.gov NCT01977833 Funding No specific funding was received for the study.
Authors: Andrey Loboda; Walter K Kraft; Bernard Fine; Jeffrey Joseph; Michael Nebozhyn; Chunsheng Zhang; Yudong He; Xia Yang; Christopher Wright; Mark Morris; Ira Chalikonda; Mark Ferguson; Valur Emilsson; Amy Leonardson; John Lamb; Hongyue Dai; Eric Schadt; Howard E Greenberg; Pek Yee Lum Journal: BMC Med Genomics Date: 2009-02-09 Impact factor: 3.063
Authors: Jesus Lopez-Minguez; Hassan S Dashti; Juan J Madrid-Valero; Juan A Madrid; Richa Saxena; Frank A J L Scheer; Juan R Ordoñana; Marta Garaulet Journal: Clin Nutr Date: 2018-03-12 Impact factor: 7.324
Authors: Elizabeth F Sutton; Robbie Beyl; Kate S Early; William T Cefalu; Eric Ravussin; Courtney M Peterson Journal: Cell Metab Date: 2018-05-10 Impact factor: 27.287
Authors: Deanna M Arble; Joseph Bass; Cecilia Diniz Behn; Matthew P Butler; Etienne Challet; Charles Czeisler; Christopher M Depner; Joel Elmquist; Paul Franken; Michael A Grandner; Erin C Hanlon; Alex C Keene; Michael J Joyner; Ilia Karatsoreos; Philip A Kern; Samuel Klein; Christopher J Morris; Allan I Pack; Satchidananda Panda; Louis J Ptacek; Naresh M Punjabi; Paolo Sassone-Corsi; Frank A Scheer; Richa Saxena; Elizabeth R Seaquest; Matthew S Thimgan; Eve Van Cauter; Kenneth P Wright Journal: Sleep Date: 2015-12-01 Impact factor: 5.849
Authors: Jingyi Qian; Chiara Dalla Man; Christopher J Morris; Claudio Cobelli; Frank A J L Scheer Journal: Diabetes Obes Metab Date: 2018-07-02 Impact factor: 6.577
Authors: Victoria A Acosta-Rodríguez; Filipa Rijo-Ferreira; Carla B Green; Joseph S Takahashi Journal: Nat Commun Date: 2021-05-17 Impact factor: 14.919